Other companies are working on their own weight-loss pills: Eli Lilly, which makes Zepbound, is developing a GLP-1 pill, orforglipron, for weight loss and type 2 diabetes, with FDA approval anticipated for March 2026
Lifestyle changes, like eating healthier and exercising more, are essential for optimal effectiveness and to improve your chances of maintaining a healthy weight after you stop taking the medication. As an RD, I appreciate that Ro Body offers a convenient way for people to access GLP-1 medications to assist with their weight loss efforts
Understanding the evidence, potential interactions, and your individual risk profile is essential before initiating or adjusting either medication
On May 14, 2025, the plaintiffs and the defendant corporations will meet to discuss a reliable diagnostic process for identifying gastroparesis
Lets keep the discussion going in the comments below
G., Meyer, M., & Adermann, K